| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.03 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.03 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.03 |